A Randomized Pilot Study of Four Dosing Schemes of Sublingual Methazolamide in Glaucoma Patients
Sublingual methazolamide demonstrated effective IOP reduction with a favorable safety profile. Twice-daily dosing may offer more sustained IOP control. These findings support further investigation into sublingual methazolamide as an alternative glaucoma treatment.
Authors
- S. McWilliams
- Leonard K Seibold
- Nicholas Tan (ORCID: https://orcid.org/0000-0002-7362-0038)
- Malik Y Kahook
- Jennifer L Patnaik
Institutions
- University of Colorado Anschutz Medical Campus (US)
Publication Details
- Journal
- Clinical ophthalmology
- Published
- 2024-12-01
- DOI
- https://doi.org/10.2147/opth.s496420
- Citations
- 1
- Primary Topic
- Glaucoma and retinal disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.54